VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist. VIPhyb can inhibit VIP signaling, increase T-cell immunity and downregulate PD1. VIPhyb can inhibit cancer cell proliferation. VIPhyb can reduce inflammatory cytokine expression. VIPhyb can enhance viral clearance. VIPhyb can be used for the researches of cancer, infection and inflammation and immunology, such as non-small cell lung cancer (NSCLC), cytomegalovirus infection and colitis[1][2][3][4].
Molecular Weight:
3467.06
Purity:
99.73
CAS Number:
[125093-93-8]
Formula:
C154H257N49O40S
Target:
CMV,PD-1/PD-L1
Application Notes:
MCE Product type: Peptides
* VAT and and shipping costs not included. Errors and price changes excepted
